Thermo Fisher Scientific (NYSE:TMO) Shares Cross Below 50-Day Moving Average - Should You Sell?

Thermo Fisher Scientific logo with Healthcare background
Image from MarketBeat Media, LLC.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report)'s share price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $678.63 and traded as low as $667.94. Thermo Fisher Scientific shares last traded at $668.8920, with a volume of 2,360,257 shares.

More Thermo Fisher Scientific News

These are some of the TMO news items that stood out recently:

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMO. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a research note on Wednesday, September 9th. The Goldman Sachs Group boosted their price target on shares of Thermo Fisher Scientific from $650.00 to $780.00 and gave the stock a "buy" rating in a research note on Monday, September 21st. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. CLSA began coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an "outperform" rating and a C$748.00 price objective on the stock. Finally, DZ Bank downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Friday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $683.64.

Get Our Latest Stock Analysis on TMO

Thermo Fisher Scientific Trading Down 2.9%

The firm's 50 day moving average is $678.63 and its 200 day moving average is $559.30. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market capitalization of $247.84 billion, a PE ratio of 35.28, a P/E/G ratio of 2.82 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $0.28. The company had revenue of $12.14 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. Thermo Fisher Scientific's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.79 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.92%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 2,831 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the sale, the vice president owned 11,560 shares of the company's stock, valued at $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank OZK bought a new position in Thermo Fisher Scientific during the second quarter valued at $1,096,000. Ausdal Financial Partners Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth about $456,000. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $15,501,867,000. German American Bancorp Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $4,920,000. Finally, Andra AP fonden grew its holdings in Thermo Fisher Scientific by 25.3% during the 2nd quarter. Andra AP fonden now owns 72,457 shares of the medical research company's stock valued at $36,327,000 after purchasing an additional 14,643 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

(Get Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Thermo Fisher Scientific Right Now?

Before you consider Thermo Fisher Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.

While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines